What Is the First-Line Treatment for Distal Renal Tubular Acidosis (dRTA)?

Clinical Scenario

Distal renal tubular acidosis (dRTA) presents with low plasma bicarbonate and concomitant hypokalaemia. Severity at diagnosis varies — from marked acidosis to cases detected through family screening with near-normal bicarbonate levels. Management must be adapted to the patient’s age and biochemical status at presentation, from infancy through adulthood.

Treatment Approach

First-line management centres on alkali supplementation. The choice of alkali formulation is guided by the patient’s potassium status; depending on the formulation selected, separate electrolyte supplementation may also be required. Alongside pharmacological treatment, dietary measures that reduce acid load are recommended.

Full dosing algorithm, formulation selection, monitoring schedule, and complete age-specific regimen available in the structured protocol →

Treatment Goals

The objective is to maintain plasma bicarbonate (HCO₃⁻), chloride (Cl⁻), and potassium (K⁺), as well as urinary calcium excretion, within age-appropriate normal ranges. In infants, plasma bicarbonate should be monitored closely and doses adjusted until a stable normal level is reached.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/ndt/gfab171

We recommend using alkali supplementation for the treatment of dRTA.
Use of K⁺-containing alkali addresses the concomitant hypokalaemia.
If a Na⁺-containing formulation is used, separate K⁺ supplementation may be necessary to maintain normal plasma levels.
We recommend informing patients of the effects of diet on acid load and alkali supplementation.
We recommend maintaining plasma HCO₃⁻, Cl⁻ and K⁺, as well as urinary calcium excretion within the age-appropriate normal range.
‘Trough’ plasma HCO₃⁻ levels should be checked every 24–48 h and the dose adjusted accordingly, until a stable normal plasma HCO₃⁻ level has been reached.

View source ↗